NCT00134017View on ClinicalTrials.gov

Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Chronic Myeloproliferative DisordersLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic Syndromes
Interventions
DRUG

Busulfan

Days -7 to -4: 4 mg/kg PO daily OR 3.2 mg/kg IV daily OR 160 mg/m\^2 daily (for pediatric recipients)

DRUG

Cyclophosphamide

Days -3, -2, +3, +4: 50 mg/kg IV daily

Trial Locations (1)

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00134017 - Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer | Biotech Hunter | Biotech Hunter